CervoMed Inc. CRVO
CervoMed Inc. (Nasdaq: CRVO) is a CNS/neurology/psychiatry drug developer. Its lead program, neflamapimod, is in Phase 2 for Dementia with Lewy bodies (DLB); also nfvPPA, RAS, ALS. Its next catalyst on record is neflamapimod DLB: Initiation of planned Phase 3 trial (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: neflamapimod DLB — Initiation of planned Phase 3 trial (H2 2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| neflamapimod | Dementia with Lewy bodies (Phase 2b RewinD-LB completed; Phase 3 planned) | small molecule | Phase 2 |
| neflamapimod | Non-fluent variant primary progressive aphasia (nfvPPA), Phase 2a | small molecule | Phase 2 |
| neflamapimod | Reversible aphasia syndrome / RAS (RESTORE Phase 2a) | small molecule | Phase 2 |
| neflamapimod | ALS (EXPERTS-ALS) | small molecule | Pre-clinical |
Recent results and decisions
- Aug 4, 2026n/a UK MHRA-led ILAP granted neflamapimod an Innovation Passport for DLB (ex-US regulatory designation).
Neflamapimod selected for the ILAP by joint consensus
Filing - Aug 4, 2026completed enrollment CervoMed recently completed enrollment in its Phase 2a trial of neflamapimod in nfvPPA.
CervoMed also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nfvPPA
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.